Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine.
hypothalamus
kappa opioid receptors
migraine
prolactin
stress
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
27 08 2022
27 08 2022
Historique:
received:
26
05
2021
revised:
17
02
2022
accepted:
13
03
2022
pubmed:
25
3
2022
medline:
31
8
2022
entrez:
24
3
2022
Statut:
ppublish
Résumé
Migraine headache results from activation of meningeal nociceptors, however, the hypothalamus is activated many hours before the emergence of pain. How hypothalamic neural mechanisms may influence trigeminal nociceptor function remains unknown. Stress is a common migraine trigger that engages hypothalamic dynorphin/kappa opioid receptor (KOR) signalling and increases circulating prolactin. Prolactin acts at both long and short prolactin receptor isoforms that are expressed in trigeminal afferents. Following downregulation of the prolactin receptor long isoform, prolactin signalling at the prolactin receptor short isoform sensitizes nociceptors selectively in females. We hypothesized that stress may activate the kappa opioid receptor on tuberoinfundibular dopaminergic neurons to increase circulating prolactin leading to female-selective sensitization of trigeminal nociceptors through dysregulation of prolactin receptor isoforms. A mouse two-hit hyperalgesic priming model of migraine was used. Repeated restraint stress promoted vulnerability (i.e. first-hit priming) to a subsequent subthreshold (i.e. second-hit) stimulus from inhalational umbellulone, a TRPA1 agonist. Periorbital cutaneous allodynia served as a surrogate of migraine-like pain. Female and male KORCre; R26lsl-Sun1-GFP mice showed a high percentage of KORCre labelled neurons co-localized in tyrosine hydroxylase-positive cells in the hypothalamic arcuate nucleus. Restraint stress increased circulating prolactin to a greater degree in females. Stress-primed, but not control, mice of both sexes developed periorbital allodynia following inhalational umbellulone. Gi-DREADD activation (i.e. inhibition through Gi-coupled signalling) in KORCre neurons in the arcuate nucleus also increased circulating prolactin and repeated chemogenetic manipulation of these neurons primed mice of both sexes to umbellulone. Clustered regularly interspaced short palindromic repeats-Cas9 deletion of the arcuate nucleus KOR prevented restraint stress-induced prolactin release in female mice and priming from repeated stress episodes in both sexes. Inhibition of circulating prolactin occurred with systemic cabergoline, a dopamine D2 receptor agonist, blocked priming selectively in females. Repeated restraint stress downregulated the prolactin receptor long isoform in the trigeminal ganglia of female mice. Deletion of prolactin receptor in trigeminal ganglia by nasal clustered regularly interspaced short palindromic repeats-Cas9 targeting both prolactin receptor isoforms prevented stress-induced priming in female mice. Stress-induced activation of hypothalamic KOR increases circulating prolactin resulting in trigeminal downregulation of prolactin receptor long and pain responses to a normally innocuous TRPA1 stimulus. These are the first data that provide a mechanistic link between stress-induced hypothalamic activation and the trigeminal nociceptor effectors that produce trigeminal sensitization and migraine-like pain. This sexually dimorphic mechanism may help to explain female prevalence of migraine. KOR antagonists, currently in phase II clinical trials, may be useful as migraine preventives in both sexes, while dopamine agonists and prolactin/ prolactin receptor antibodies may improve therapy for migraine, and other stress-related neurological disorders, in females.
Identifiants
pubmed: 35325034
pii: 6553687
doi: 10.1093/brain/awac104
pmc: PMC9890468
doi:
Substances chimiques
Receptors, Opioid, kappa
0
Receptors, Prolactin
0
Prolactin
9002-62-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2894-2909Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR063772
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS096705
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS119263
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Neuron. 2012 Jan 26;73(2):219-34
pubmed: 22284178
Cephalalgia. 2017 Jul;37(8):780-794
pubmed: 28376659
Front Neurol. 2020 Mar 25;11:140
pubmed: 32269547
Cephalalgia. 2003 Jul;23(6):451-5
pubmed: 12807524
Cephalalgia. 2022 Mar;42(3):197-208
pubmed: 34510920
J Comp Neurol. 1985 Sep 8;239(2):127-54
pubmed: 2864362
Peptides. 2007 Aug;28(8):1611-4
pubmed: 17698246
Methods Mol Biol. 2010;617:105-14
pubmed: 20336417
J Neurosci. 2006 Aug 2;26(31):8126-36
pubmed: 16885226
Trends Neurosci. 2020 Aug;43(8):635-648
pubmed: 32620290
ACS Chem Neurosci. 2014 Nov 19;5(11):1085-96
pubmed: 25138211
Cephalalgia. 2021 Mar;41(3):305-317
pubmed: 32985222
Brain Res. 2010 Feb 16;1314:44-55
pubmed: 19716811
Pain. 2003 Aug;104(3):693-700
pubmed: 12927642
Cephalalgia. 2019 Dec;39(14):1762-1775
pubmed: 31550910
Neuropsychopharmacology. 2006 Oct;31(10):2255-63
pubmed: 16554744
Brain Res. 1973 Mar 15;51:193-205
pubmed: 4706010
J Neurosci. 2019 May 29;39(22):4323-4331
pubmed: 30962278
J Headache Pain. 2008 Apr;9(2):103-7
pubmed: 18256782
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8837-42
pubmed: 27432990
Front Neurol. 2010 Aug 23;1:16
pubmed: 21188255
Headache. 2013 Jul-Aug;53(7):1104-15
pubmed: 23594167
J Headache Pain. 2017 Dec;18(1):73
pubmed: 28733942
Headache. 2006 Oct;46(9):1334-43
pubmed: 17040331
Eur J Endocrinol. 2004 Jul;151(1):61-5
pubmed: 15248823
BMC Public Health. 2014 Jul 03;14:678
pubmed: 24993032
Front Pharmacol. 2014 Nov 17;5:253
pubmed: 25452729
Brain Res. 2003 Aug 8;980(2):213-20
pubmed: 12867261
Neurosci Lett. 1993 Nov 12;162(1-2):161-4
pubmed: 7907172
eNeuro. 2020 Jul 23;7(4):
pubmed: 32561573
Cephalalgia. 2017 May;37(6):560-570
pubmed: 27206958
J Comp Neurol. 2020 Jul 15;528(11):1833-1855
pubmed: 31950494
Pain. 2018 May;159(5):919-928
pubmed: 29369967
Headache. 2013 Sep;53(8):1278-99
pubmed: 23808666
Nat Rev Endocrinol. 2019 Jun;15(6):356-365
pubmed: 30899100
Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1154-64
pubmed: 24022869
Obstet Gynecol Int. 2018 Dec 3;2018:9253083
pubmed: 30627169
Neurol Clin. 2019 Nov;37(4):651-671
pubmed: 31563225
Lancet. 2018 Mar 31;391(10127):1315-1330
pubmed: 29523342
J Neurosci. 2008 Jan 9;28(2):407-14
pubmed: 18184783
Front Psychiatry. 2014 Dec 08;5:170
pubmed: 25538632
Endocr Rev. 2008 Feb;29(1):1-41
pubmed: 18057139
Eur J Pharmacol. 2001 Jul 6;423(2-3):243-9
pubmed: 11448491
Cephalalgia. 2011 Jan;31(1):6-12
pubmed: 20974609
Gene Ther. 2017 Aug;24(8):482-486
pubmed: 28682314
Front Cell Neurosci. 2018 Sep 19;12:294
pubmed: 30283302
Exp Neurol. 2018 Sep;307:45-51
pubmed: 29856967
Cephalalgia. 2019 Nov;39(13):1710-1719
pubmed: 31466456
J Neurosci. 1997 Jun 15;17(12):4886-94
pubmed: 9169546
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
pubmed: 12388666
Pain. 2019 Jul;160(7):1494-1501
pubmed: 31219950
Physiol Rev. 2000 Oct;80(4):1523-631
pubmed: 11015620
Neurobiol Dis. 2014 Aug;68:200-14
pubmed: 24662368
Pain. 2020 May;161(5):1037-1043
pubmed: 31895266
J Headache Pain. 2016 Dec;17(1):94
pubmed: 27770403
J Headache Pain. 2006 Apr;7(2):83-9
pubmed: 16538425
J Neurosci. 2020 Sep 9;40(37):7080-7090
pubmed: 32801151
Neurology. 2014 Apr 22;82(16):1395-401
pubmed: 24670889
Mol Cell Neurosci. 1994 Aug;5(4):327-35
pubmed: 7804602
Pain. 2011 Jan;152(1):38-44
pubmed: 21075522
Neurosci Lett. 2005 Jul 22-29;383(1-2):7-11
pubmed: 15936504
Neuron. 2018 Mar 7;97(5):1004-1021
pubmed: 29518355
Pain. 2020 Nov;161(11):2539-2550
pubmed: 32541386
iScience. 2019 Oct 25;20:449-465
pubmed: 31627131
J Neurosci Res. 2017 Jan 2;95(1-2):587-593
pubmed: 27870430
Genesis. 2016 Jan;54(1):29-37
pubmed: 26575788
Neuron. 2015 Jun 17;86(6):1369-84
pubmed: 26087164
Headache. 2012 Oct;52 Suppl 2:102-6
pubmed: 23030541
J Med Chem. 2019 Feb 28;62(4):1761-1780
pubmed: 30707578
Exp Neurol. 2015 Jan;263:214-20
pubmed: 25447936
Trends Neurosci. 1995 Jan;18(1):22-9
pubmed: 7535487
Physiol Rev. 2017 Apr;97(2):553-622
pubmed: 28179394
Neuropharmacology. 2014 Feb;77:131-44
pubmed: 24071566
Neuron. 2010 Jan 28;65(2):217-29
pubmed: 20152128
Psychoneuroendocrinology. 2011 Nov;36(10):1530-9
pubmed: 21621331
Headache. 2013 Jan;53(1):81-92
pubmed: 23078241
Endocrinology. 1995 Dec;136(12):5745-50
pubmed: 7588332
J Pharmacol Exp Ther. 1999 Jan;288(1):260-9
pubmed: 9862779
J Psychopharmacol. 2008 Mar;22(2 Suppl):12-9
pubmed: 18477617
Ann Neurol. 2021 Jun;89(6):1129-1144
pubmed: 33749851
Endocr Rev. 2001 Dec;22(6):724-63
pubmed: 11739329
Cephalalgia. 2014 Jun;34(7):493-502
pubmed: 24351278
J Neurol. 2017 Sep;264(9):2031-2039
pubmed: 28321564
Brain. 2012 Feb;135(Pt 2):376-90
pubmed: 22036959
Ann Neurol. 2010 Mar;67(3):325-37
pubmed: 20373344
Pharmacol Biochem Behav. 1983 Jun;18(6):967-71
pubmed: 6310644
Drugs. 1998;55 Suppl 1:10-6
pubmed: 9483165
Neuroscience. 2019 Sep 1;415:1-9
pubmed: 31299346
Cephalalgia. 2020 Dec;40(14):1535-1550
pubmed: 33131305
J Neuroendocrinol. 2017 Jun;29(6):
pubmed: 28425631
Brain. 2016 Jul;139(Pt 7):1987-93
pubmed: 27190019
Arq Neuropsiquiatr. 2020 Jan;78(1):28-33
pubmed: 32074187
Brain Res. 1998 Oct 5;807(1-2):228-33
pubmed: 9757048
Life Sci. 1992;50(17):1201-5
pubmed: 1569828
Sci Transl Med. 2020 Feb 5;12(529):
pubmed: 32024801
J Psychosom Res. 2015 Mar;78(3):228-36
pubmed: 25598410
J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22
pubmed: 10404830
Cephalalgia. 2007 May;27(5):394-402
pubmed: 17403039
Cephalalgia. 2020 Dec;40(14):1614-1621
pubmed: 32830513
J Neuroendocrinol. 2019 Aug;31(8):e12759
pubmed: 31231869